Skip to main content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SAVOIR trial

Toni Choueiri discusses how the phase 3 SAVOIR trial of savolitinib in MET-driven papillary renal cell carcinoma could inform future research despite being terminated early (4:23).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits